Literature DB >> 33052435

Drugging the "undruggable" microRNAs.

Dejun Liu1, Xinqiang Wan2, Xiangxiang Shan3, Rengen Fan4, Wenzhang Zha5.   

Abstract

As a naturally occurring class of gene regulators, microRNAs (miRNAs) have attracted much attention as promising targets for therapeutic development. However, RNAs including miRNAs have long been considered undruggable, and most efforts have been devoted to using synthetic oligonucleotides to regulate miRNAs. Encouragingly, recent findings have revealed that miRNAs can also be drugged with small molecules that directly target miRNAs. In this review paper, we give a summary of recently emerged small-molecule inhibitors (SMIs) and small-molecule degraders (SMDs) for miRNAs. SMIs are small molecules that directly bind to miRNAs to inhibit their biogenesis, and SMDs are bifunctional small molecules that upon binding to miRNAs induce miRNA degradation. Strategies for discovering SMIs and developing SMDs were summarized. Applications of SMIs and SMDs in miRNA inhibition and cancer therapy were also introduced. Overall, SMIs and SMDs introduced here have high potency and specificity in miRNA inhibition. We envision that these small molecules will pave the way for developing novel therapeutics toward miRNAs that were previously considered undruggable.

Entities:  

Keywords:  Cancer therapy; Drug development; MicroRNA; Small-molecule degrader; Small-molecule inhibitor

Year:  2020        PMID: 33052435     DOI: 10.1007/s00018-020-03676-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  57 in total

Review 1.  Targeting RNA with small molecules.

Authors:  Yitzhak Tor
Journal:  Chembiochem       Date:  2003-10-06       Impact factor: 3.164

Review 2.  The druggable genome.

Authors:  Andrew L Hopkins; Colin R Groom
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

Review 3.  Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics.

Authors:  Rengen Fan; Chaocheng Xiao; Xinqiang Wan; Wenzhang Cha; Yufeng Miao; Yong Zhou; Chenglin Qin; Ting Cui; Fenglian Su; Xiangxiang Shan
Journal:  RNA Biol       Date:  2019-04-03       Impact factor: 4.652

Review 4.  RNA-based recognition and targeting: sowing the seeds of specificity.

Authors:  Stanislaw A Gorski; Jörg Vogel; Jennifer A Doudna
Journal:  Nat Rev Mol Cell Biol       Date:  2017-02-15       Impact factor: 94.444

Review 5.  MicroRNA biogenesis pathways in cancer.

Authors:  Shuibin Lin; Richard I Gregory
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 6.  Metazoan MicroRNAs.

Authors:  David P Bartel
Journal:  Cell       Date:  2018-03-22       Impact factor: 41.582

Review 7.  MicroRNAs as novel biological targets for detection and regulation.

Authors:  Jinbo Li; Subee Tan; Romain Kooger; Chenyu Zhang; Yan Zhang
Journal:  Chem Soc Rev       Date:  2014-01-21       Impact factor: 54.564

Review 8.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

Review 9.  The microcosmos of cancer.

Authors:  Amaia Lujambio; Scott W Lowe
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

10.  miRBase: from microRNA sequences to function.

Authors:  Ana Kozomara; Maria Birgaoanu; Sam Griffiths-Jones
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  2 in total

Review 1.  Circular RNA and Its Roles in the Occurrence, Development, Diagnosis of Cancer.

Authors:  Yue Zhang; Xinyi Zhang; Yumeng Xu; Shikun Fang; Ying Ji; Ling Lu; Wenrong Xu; Hui Qian; Zhao Feng Liang
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

2.  Exosomes with high level of miR-181c from bone marrow-derived mesenchymal stem cells inhibit inflammation and apoptosis to alleviate spinal cord injury.

Authors:  Meng Zhang; Lin Wang; Sihua Huang; Xijing He
Journal:  J Mol Histol       Date:  2021-02-06       Impact factor: 2.611

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.